u/ninjagorilla

Reddit r/ValueInvesting
· tracked since Aug 2026
Calls
3
Win Rate
0.0%
return
-1.4%
Calls 3 1 Posts tracked · 0.2/day
Calls
7d 3
30d 3
90d 3
Best Calls
No live winners yet
Worst Calls
GOOG Long -2.7%
LLY Long -1.5%
MELI Long -0.0%
Most Mentioned
GOOGL ×1
LLY ×1
MELI ×1
Recent Calls
LLY Long 4 days ago
GOOG Long 4 days ago
MELI Long 4 days ago
Win Rate 0% Long 3 Short 0
Win Rate
7d
30d
90d
Average Return -1.4% Long Return -1.4% Short Return -
Average Return
7d
30d
90d
Loading charts...
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Aug 28
$343.46
-2.7%
Alphabet has a highly diversified portfolio including search, AI, Waymo, quantum computing, and biotech holdings. This extreme diversification acts like an ETF, providing multiple long-term growth verticals beyond its core advertising business. Strong long-term buy due to broad exposure to future technological monopolies and moonshots. Regulatory antitrust break-ups or failure to profitably monetize moonshot projects.
Alphabet has a highly diversified portfolio including search, AI, Waymo, quantum computing, and biotech holdings. This extreme diversification acts like an ETF, providing multiple long-term growth verticals beyond its core advertising business. Strong long-term buy due to broad exposure to future technological monopolies and moonshots. Regulatory antitrust break-ups or failure to profitably monetize moonshot projects.
Hyperscalers
Long
Aug 28
$1176.87
-1.5%
Revenue increased 47% YoY, supported by a huge pipeline beyond weight loss, including immunity, oncology, and the newly approved Foundayo. Intensive efforts in AI drug design and a broad, expanding pipeline secure long-term, compounding revenue growth. Considered a "Mag 8" stock with a highly visible and bright future in next-generation pharma. Clinical trial failures, patent cliffs, or regulatory hurdles for experimental drugs.
Revenue increased 47% YoY, supported by a huge pipeline beyond weight loss, including immunity, oncology, and the newly approved Foundayo. Intensive efforts in AI drug design and a broad, expanding pipeline secure long-term, compounding revenue growth. Considered a "Mag 8" stock with a highly visible and bright future in next-generation pharma. Clinical trial failures, patent cliffs, or regulatory hurdles for experimental drugs.
GLP-1 / Obesity
Long
Aug 28
$1963.52
-0.0%
Management explicitly stated they prioritize long-term engagement, growth, and scale over near-term profitability. Reinvesting capital into scale and user engagement builds a wider, more defensible economic moat in Latin America. A strong long-term hold based on management's growth-focused capital allocation strategy. Short-term margin compression could lead to stock volatility and test investor patience.
Management explicitly stated they prioritize long-term engagement, growth, and scale over near-term profitability. Reinvesting capital into scale and user engagement builds a wider, more defensible economic moat in Latin America. A strong long-term hold based on management's growth-focused capital allocation strategy. Short-term margin compression could lead to stock volatility and test investor patience.
Retail & Mobility
Showing 3 of 3 calls · sorted by mentions

u/ninjagorilla has 3 trade ideas tracked on Buzzberg across 3 tickers since August 2026. Most covered: GOOGL, LLY, MELI.